Angioblast Systems

Angioblast Systems is a biotechnology company that aims to advance cardiovascular health through innovative biotech solutions and strategic partnerships. Established in 2001, the company specializes in developing and commercializing therapeutic products for cardiovascular diseases. Their product range includes adult stem cells, protein therapeutics, gene silencing, small molecule peptides and antibodies, cytokines, antigen-receptor inhibitors, DNAzymes, and MPC products targeting conditions such as heart failure, heart attacks, peripheral artery diseases, and wound ulcers. One of the key highlights of the company is its strategic alliance with Mesoblast Limited. Based in New York, New York, Angioblast Systems, Inc. is at the forefront of innovative biotech solutions aimed at addressing critical cardiovascular issues. With a strong emphasis on research and development, this biotechnology startup presents investment opportunities in the burgeoning field of cardiovascular health solutions, where groundbreaking innovations have the potential to make a significant impact.